Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis2018-01-17T17:04:46-05:00
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring2018-01-17T17:03:31-05:00
